---
schema_version: "secwatch.filing_event.v1"
accession: "0001145197-24-000043"
form_type: "8-K"
ticker: "PODD"
cik: "0001145197"
company_name: "INSULET CORP"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:17:53.910039+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Insulet Q3 revenue +26% to $543.9M; beats guidance; raises FY outlook; Omnipod 5 cleared for type 2 diabetes

## Summary
- Revenue $543.9M (+25.7% YoY); Omnipod $533.6M (+26.4%); U.S. +23.4%, International +36.1%.
- GAAP net income $77.5M ($1.08 EPS) vs $51.9M ($0.74); adjusted net income $64.2M ($0.90 EPS).
- Gross margin 69.3% (+150bps); operating income $88.1M (16.2% of revenue); adjusted EBITDA $126.1M (23.2%).
- Received FDA clearance for Omnipod 5 for type 2 diabetes; first AID system for both T1 and T2.
- Raised full-year revenue and margin guidance; Q3 revenue exceeded high end of 21% constant currency guidance.

## SEC filing metadata
- accession: 0001145197-24-000043
- form_type: 8-K
- ticker: PODD
- cik: 0001145197
- company_name: INSULET CORP
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1145197/000114519724000043/0001145197-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1145197/000114519724000043/podd-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001145197-24-000043
- JSON: https://secwatch.observer/filing/0001145197-24-000043.json
- Plain text: https://secwatch.observer/filing/0001145197-24-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.